(Bloomberg) — Amgen Inc. will take a 20.5% stake in Chinese-American drug developer BeiGene Ltd under a deal to develop and commercialize about two dozen of Amgens on-market and experimental cancer drugs in China.
Amgen will buy about $2.7 billion worth of …
